calcipotriene 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
Vitamin D analogues/derivatives 465 112965-21-6

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • calcipotriene
  • calcipotriol
  • calciptriol
  • daivonex
  • dovonex
  • calcipotriene hydrate
  • calcipotriol hydrate
a topical dermatologic for the treatment of moderate plaque psoriasis
  • Molecular weight: 412.61
  • Formula: C27H40O3
  • CLOGP: 5.27
  • LIPINSKI: 1
  • HAC: 3
  • HDO: 3
  • TPSA: 60.69
  • ALOGS: -4.49
  • ROTB: 5
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 0.50 % Benet LZ, Broccatelli F, Oprea TI
BA (Bioavailability) 5.50 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
kinase-safety-class ACVR2B,CDK5,EIF2AK3,GRK2,ITK,PDK1,PDK2,PDK4,PRKDC 9
pfas-class PFAS structural alert (1 = True, 0 = False) 0

Approvals:

DateAgencyCompanyOrphan
Dec. 29, 1993 FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Psoriasis 1137.82 31.14 552 16366 147202 90464327
Carotid artery thrombosis 592.68 31.14 165 16753 8927 90602602
Neurologic neglect syndrome 592.53 31.14 164 16754 8683 90602846
Skin haemorrhage 580.14 31.14 198 16720 21182 90590347
Adjustment disorder 560.53 31.14 160 16758 9482 90602047
Personality disorder 537.25 31.14 164 16754 12280 90599249
Skin exfoliation 515.76 31.14 252 16666 67661 90543868
Sensory loss 500.54 31.14 170 16748 17905 90593624
Hemiplegia 491.08 31.14 163 16755 15997 90595532
Arterial occlusive disease 482.29 31.14 151 16767 12295 90599234
Gangrene 481.40 31.14 152 16766 12724 90598805
Affect lability 481.07 31.14 165 16753 17898 90593631
Sinus congestion 477.55 31.14 183 16735 27241 90584288
Coordination abnormal 476.56 31.14 171 16747 21185 90590344
Motor dysfunction 467.13 31.14 164 16754 19066 90592463
Sneezing 448.41 31.14 179 16739 29690 90581839
Respiratory tract congestion 438.52 31.14 172 16746 27238 90584291
Sinus disorder 430.42 31.14 181 16737 34266 90577263
Eating disorder 396.38 31.14 161 16757 27912 90583617
Hemiparesis 383.54 31.14 163 16755 31656 90579873
Muscle spasticity 370.38 31.14 164 16754 35158 90576371
Aphasia 343.26 31.14 165 16753 42647 90568882
Cystitis 311.37 31.14 179 16739 66539 90544990
Dysarthria 311.25 31.14 167 16751 54315 90557214
Angina pectoris 308.09 31.14 149 16769 39011 90572518
Rhinorrhoea 301.70 31.14 194 16724 88122 90523407
Influenza like illness 280.08 31.14 179 16739 80432 90531097
Cataract 228.10 31.14 151 16767 71941 90539588
Influenza 218.72 31.14 192 16726 139072 90472457
Dysphagia 203.27 31.14 168 16750 112110 90499419
Cerebrovascular accident 189.31 31.14 168 16750 123365 90488164
Palpitations 169.05 31.14 165 16753 136563 90474966
Chest discomfort 159.99 31.14 161 16757 138204 90473325
Skin plaque 153.81 31.14 61 16857 9914 90601615
Arthritis 151.54 31.14 171 16747 167144 90444385
Blood pressure inadequately controlled 131.84 31.14 48 16870 6176 90605353
Diabetes mellitus inadequate control 122.91 31.14 63 16855 18621 90592908
Muscular weakness 118.25 31.14 168 16750 206498 90405031
Blood pressure increased 116.81 31.14 163 16755 197054 90414475
Exercise tolerance decreased 115.80 31.14 46 16872 7505 90604024
Multiple drug therapy 94.75 31.14 39 16879 6970 90604559
Anxiety 93.17 31.14 189 16729 309583 90301946
Cough 90.23 31.14 207 16711 368755 90242774
Sinusitis 82.23 31.14 191 16727 342897 90268632
Nasopharyngitis 82.04 31.14 212 16706 406892 90204637
Drug ineffective 80.31 31.14 485 16433 1383813 89227716
Papule 70.67 31.14 33 16885 7969 90603560
Gastrointestinal disorder 65.99 31.14 147 16771 256540 90354989
Malaise 64.96 31.14 248 16670 585738 90025791
Infected dermal cyst 51.61 31.14 13 16905 474 90611055
General physical health deterioration 51.18 31.14 4 16914 355111 90256418
Drug hypersensitivity 51 31.14 12 16906 463597 90147932
Rheumatoid arthritis 49.99 31.14 165 16753 362449 90249080
Depressed mood 48.24 31.14 53 16865 50169 90561360
Confusional state 48.21 31.14 170 16748 386035 90225494
Pain of skin 44.40 31.14 31 16887 16051 90595478
Synovitis 44.10 31.14 5 16913 329747 90281782
Headache 43.31 31.14 292 16626 862454 89749075
Anaemia 43.27 31.14 7 16911 352795 90258734
Contraindicated product administered 42.45 31.14 5 16913 320134 90291395
Gallbladder rupture 41.09 31.14 11 16907 511 90611018
Death 40.96 31.14 17 16901 456534 90154995
Psoriatic arthropathy 40.93 31.14 114 16804 228221 90383308
Decreased appetite 40.90 31.14 10 16908 376530 90234999
Seborrhoeic keratosis 40.63 31.14 17 16901 3163 90608366
Weight increased 40.09 31.14 14 16904 417913 90193616
Dizziness 39.93 31.14 31 16887 589253 90022276
Drug intolerance 38.05 31.14 18 16900 447573 90163956
Acute kidney injury 37.87 31.14 7 16911 320380 90291149
Hypersensitivity 37.57 31.14 19 16899 454658 90156871
Arthropathy 37.37 31.14 11 16907 366231 90245298
Hypotension 36.61 31.14 8 16910 325389 90286140
Fall 35.07 31.14 180 16738 481630 90129899
Hepatic enzyme increased 33.05 31.14 13 16905 360723 90250806
Hypoaesthesia 32.86 31.14 9 16909 314201 90297328
Stomatitis 32.47 31.14 6 16912 274692 90336837

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Psoriasis 673.75 24.24 241 4736 48363 42567995
Drug ineffective 318.71 24.24 375 4602 629822 41986536
Psoriatic arthropathy 201.89 24.24 84 4893 24883 42591475
Skin exfoliation 101.14 24.24 62 4915 41491 42574867
Therapeutic product effect incomplete 96.76 24.24 74 4903 70865 42545493
Skin plaque 80.40 24.24 29 4948 5834 42610524
Treatment failure 80.30 24.24 63 4914 62561 42553797
Onychoclasis 72.15 24.24 22 4955 2630 42613728
Guttate psoriasis 71.92 24.24 16 4961 550 42615808
Papule 58.71 24.24 23 4954 5803 42610555
Malignant melanoma stage I 50.07 24.24 9 4968 100 42616258
Product dose omission issue 47.43 24.24 73 4904 154292 42462066
Pruritus 42.93 24.24 78 4899 188693 42427665
Keratoacanthoma 39.99 24.24 11 4966 913 42615445
Rash 37.95 24.24 93 4884 276861 42339497
Arthralgia 37.12 24.24 77 4900 205161 42411197
Therapeutic product ineffective 33.46 24.24 10 4967 1115 42615243
Superficial spreading melanoma stage unspecified 31.59 24.24 7 4970 236 42616122
Panic attack 30.76 24.24 18 4959 11027 42605331
Erythema 28.64 24.24 48 4929 108745 42507613
Nasopharyngitis 27.55 24.24 41 4936 83955 42532403
Product use in unapproved indication 27.42 24.24 64 4913 184392 42431966
Discomfort 27.26 24.24 23 4954 25196 42591162
Basal cell carcinoma 27.22 24.24 22 4955 22711 42593647
Meningitis aseptic 26.13 24.24 12 4965 4470 42611888
Hyperkeratosis 25.93 24.24 12 4965 4546 42611812

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Psoriasis 1434.54 25.58 618 17981 139375 110431325
Neurologic neglect syndrome 615.34 25.58 167 18432 9131 110561569
Carotid artery thrombosis 614.05 25.58 168 18431 9470 110561230
Skin haemorrhage 579.03 25.58 200 18399 24627 110546073
Adjustment disorder 572.59 25.58 163 18436 10632 110560068
Personality disorder 562.07 25.58 167 18432 12670 110558030
Sensory loss 504.77 25.58 174 18425 21283 110549417
Affect lability 504.77 25.58 168 18431 18469 110552231
Sinus congestion 488.13 25.58 186 18413 30273 110540427
Arterial occlusive disease 483.35 25.58 155 18444 15153 110555547
Sinus disorder 471.62 25.58 185 18414 32543 110538157
Gangrene 469.37 25.58 154 18445 16187 110554513
Sneezing 468.67 25.58 183 18416 31801 110538899
Hemiplegia 467.93 25.58 167 18432 22615 110548085
Skin exfoliation 459.77 25.58 245 18354 87406 110483294
Coordination abnormal 458.68 25.58 169 18430 25059 110545641
Motor dysfunction 456.70 25.58 167 18432 24239 110546461
Respiratory tract congestion 450.17 25.58 176 18423 30681 110540019
Eating disorder 408.19 25.58 164 18435 30694 110540006
Muscle spasticity 394.11 25.58 167 18432 35748 110534952
Hemiparesis 358.77 25.58 166 18433 43737 110526963
Cystitis 338.86 25.58 182 18417 65854 110504846
Rhinorrhoea 325.42 25.58 207 18392 102459 110468241
Aphasia 323.59 25.58 170 18429 58827 110511873
Influenza like illness 286.97 25.58 181 18418 88231 110482469
Angina pectoris 265.57 25.58 152 18447 62143 110508557
Dysarthria 264.98 25.58 169 18430 83952 110486748
Cataract 243.68 25.58 157 18442 79328 110491372
Influenza 221.30 25.58 201 18398 168900 110401800
Dysphagia 176.70 25.58 170 18429 153430 110417270
Palpitations 171.54 25.58 170 18429 159042 110411658
Cerebrovascular accident 167.15 25.58 178 18421 181106 110389594
Arthritis 164.22 25.58 170 18429 167416 110403284
Chest discomfort 152.01 25.58 166 18433 173682 110397018
Nasopharyngitis 135.80 25.58 240 18359 394121 110176579
Blood pressure inadequately controlled 127.17 25.58 48 18551 7585 110563115
Sinusitis 122.63 25.58 196 18403 296492 110274208
Blood pressure increased 119.79 25.58 180 18419 258193 110312507
Anxiety 112.32 25.58 205 18394 344873 110225827
Muscular weakness 112.19 25.58 171 18428 248297 110322403
Exercise tolerance decreased 99.64 25.58 46 18553 12021 110558679
Diabetes mellitus inadequate control 99.10 25.58 62 18537 29713 110540987
Malaise 94.35 25.58 287 18312 671532 109899168
Multiple drug therapy 93.62 25.58 39 18560 7975 110562725
Gastrointestinal disorder 92.00 25.58 154 18445 241798 110328902
Cough 89.44 25.58 222 18377 461419 110109281
Rheumatoid arthritis 82.66 25.58 166 18433 299447 110271253
Skin plaque 82.49 25.58 41 18558 12604 110558096
Psoriatic arthropathy 81.22 25.58 130 18469 196631 110374069
Headache 62.34 25.58 303 18296 882074 109688626
Onychoclasis 54.84 25.58 26 18573 7211 110563489
Death 52.54 25.58 26 18573 698843 109871857
Infusion related reaction 52.02 25.58 3 18596 381159 110189541
Acute kidney injury 51.90 25.58 21 18578 635409 109935291
Keratoacanthoma 51.21 25.58 16 18583 1432 110569268
General physical health deterioration 50.77 25.58 6 18593 425289 110145411
Anaemia 49.96 25.58 15 18584 547071 110023629
Depressed mood 49.50 25.58 56 18543 60753 110509947
Confusional state 49.41 25.58 182 18417 468498 110102202
Panic attack 49.16 25.58 40 18559 28900 110541800
Pain 48.58 25.58 300 18299 954655 109616045
Drug hypersensitivity 44.17 25.58 11 18588 454079 110116621
Secretion discharge 43.13 25.58 32 18567 20212 110550488
Malignant melanoma stage I 43.12 25.58 9 18590 155 110570545
Fall 41.61 25.58 206 18393 603276 109967424
Hypotension 40.08 25.58 19 18580 523830 110046870
Drug interaction 40.06 25.58 17 18582 500166 110070534
Pulmonary congestion 38.83 25.58 36 18563 30930 110539770
Decreased appetite 38.38 25.58 16 18583 475830 110094870
Thrombocytopenia 36.87 25.58 7 18592 348878 110221822
Infected dermal cyst 35.86 25.58 12 18587 1336 110569364
Neutropenia 34.67 25.58 10 18589 374610 110196090
Gallbladder rupture 32.75 25.58 11 18588 1239 110569461
Pain of skin 32.58 25.58 27 18572 20002 110550698
Weight increased 32.43 25.58 15 18584 419629 110151071
Guttate psoriasis 32.28 25.58 9 18590 542 110570158
Movement disorder 32.16 25.58 35 18564 36369 110534331
Off label use 32.01 25.58 137 18462 1500048 109070652
Nausea 31.30 25.58 331 18268 1235359 109335341
Contraindicated product administered 30.90 25.58 3 18596 248264 110322436
Dizziness 29.40 25.58 45 18554 698148 109872552
Platelet count decreased 28.11 25.58 3 18596 230440 110340260
Pulmonary mass 28.08 25.58 33 18566 37268 110533432
Synovitis 27.91 25.58 6 18593 274086 110296614
Erythrodermic psoriasis 27.65 25.58 11 18588 1999 110568701
Alopecia 26.72 25.58 14 18585 364739 110205961
Superficial spreading melanoma stage unspecified 26.11 25.58 7 18592 364 110570336
Condition aggravated 25.85 25.58 53 18546 734783 109835917
Respiratory failure 25.77 25.58 3 18596 215329 110355371

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC D05AX02 DERMATOLOGICALS
ANTIPSORIATICS
ANTIPSORIATICS FOR TOPICAL USE
Other antipsoriatics for topical use
ATC D05AX52 DERMATOLOGICALS
ANTIPSORIATICS
ANTIPSORIATICS FOR TOPICAL USE
Other antipsoriatics for topical use
FDA CS M0022797 Vitamin D
MeSH PA D003879 Dermatologic Agents
FDA EPC N0000175849 Vitamin D Analog
CHEBI has role CHEBI:35610 antineoplastic agent
CHEBI has role CHEBI:50177 dermatologic drug
CHEBI has role CHEBI:50748 antipsoriatic
CHEBI has role CHEBI:88188 drug allergen

Related Drugs by ATC class:

D05AX Other antipsoriatics for topical use 7 drugs
calcitriolfumaric acidroflumilasttacalcitoltapinaroftazaroteneulobetasol propionate

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Plaque psoriasis indication 200965009
Scalp psoriasis indication 238608008
Psoriasis off-label use 9014002 DOID:8893
Congenital ichthyosis of skin contraindication 13059002
Hypervitaminosis D contraindication 27712000 DOID:9971
Guttate psoriasis contraindication 37042000
Hypercalcemia contraindication 66931009 DOID:12678
Disorder of calcium metabolism contraindication 71638002 DOID:10575
Hypercalciuria contraindication 71938000
Pustular psoriasis contraindication 200973000
Telangiectasia disorder contraindication 247479008
Adrenal cortical hypofunction contraindication 386584007 DOID:10493
Atrophoderma contraindication 399979006
Peripheral vascular disease contraindication 400047006




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 13.7 acidic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
0.005% SORILUX MAYNE PHARMA N022563 Oct. 6, 2010 RX AEROSOL, FOAM TOPICAL 8629128 May 26, 2026 USE OF A CALCIPOTRIENE CONTAINING FOAM FOR THE TREATMENT OF PSORIASIS
0.005% SORILUX MAYNE PHARMA N022563 Oct. 6, 2010 RX AEROSOL, FOAM TOPICAL 8629128 May 26, 2026 USE OF CALCIPOTRIENE FOAM FOR THE TOPICAL TREATMENT OF PLAQUE PSORIASIS IN PATIENTS AGED 18 YEARS AND OLDER
0.005% SORILUX MAYNE PHARMA N022563 Oct. 6, 2010 RX AEROSOL, FOAM TOPICAL 8629128 May 26, 2026 USE OF CALCIPOTRIENE FOAM FOR THE TOPICAL TREATMENT OF PLAQUE PSORIASIS IN PATIENTS AGED 4 YEARS AND OLDER
0.005% SORILUX MAYNE PHARMA N022563 Oct. 6, 2010 RX AEROSOL, FOAM TOPICAL 8263580 May 7, 2028 USE OF A CALCIPOTRIENE CONTAINING FOAM FOR THE TREATMENT OF PSORIASIS
0.005% SORILUX MAYNE PHARMA N022563 Oct. 6, 2010 RX AEROSOL, FOAM TOPICAL 8263580 May 7, 2028 USE OF CALCIPOTRIENE FOAM FOR THE TOPICAL TREATMENT OF PLAQUE PSORIASIS IN PATIENTS AGED 4 YEARS AND OLDER
0.064%;0.005% ENSTILAR LEO PHARMA AS N207589 Oct. 16, 2015 RX AEROSOL, FOAM TOPICAL 10660908 June 10, 2031 TOPICAL TREATMENT OF PLAQUE PSORIASIS IN PATIENTS 12 YEARS AND OLDER
0.064%;0.005% ENSTILAR LEO PHARMA AS N207589 Oct. 16, 2015 RX AEROSOL, FOAM TOPICAL 10688108 June 10, 2031 TOPICAL TREATMENT OF PLAQUE PSORIASIS IN PATIENTS 12 YEARS AND OLDER
0.064%;0.005% ENSTILAR LEO PHARMA AS N207589 Oct. 16, 2015 RX AEROSOL, FOAM TOPICAL 9119781 June 10, 2031 PLAQUE PSORIASIS
0.064%;0.005% ENSTILAR LEO PHARMA AS N207589 Oct. 16, 2015 RX AEROSOL, FOAM TOPICAL 9119781 June 10, 2031 TOPICAL TREATMENT OF PLAQUE PSORIASIS IN PATIENTS 12 YEARS AND OLDER
0.064%;0.005% WYNZORA MC2 N213422 July 20, 2020 RX CREAM TOPICAL 12440499 March 18, 2039 TREATMENT OF PLAQUE PSORIASIS IN PATIENTS 18 YEARS OF AGE OR OLDER

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Vitamin D3 receptor Nuclear hormone receptor AGONIST Kd 9.51 CHEMBL CHEMBL

External reference:

IDSource
4020856 VUID
N0000148363 NUI
D01125 KEGG_DRUG
1299898 RXNORM
C0065767 UMLSCUI
CHEBI:50749 CHEBI
MC9 PDB_CHEM_ID
CHEMBL1200666 ChEMBL_ID
DB02300 DRUGBANK_ID
C055085 MESH_SUPPLEMENTAL_RECORD_UI
6376 INN_ID
143NQ3779B UNII
5288783 PUBCHEM_CID
136766 MMSL
368 MMSL
4322 MMSL
126232005 SNOMEDCT_US
395766004 SNOMEDCT_US
726717009 SNOMEDCT_US
147657-22-5 SECONDARY_CAS_RN
2778 IUPHAR_LIGAND_ID
4020856 VANDF
003941 NDDF
017139 NDDF
143NQ3779B INXIGHT DRUGS

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Calcipotriene HUMAN PRESCRIPTION DRUG LABEL 1 0713-0318 SOLUTION 0.05 mg TOPICAL ANDA 14 sections
calcipotriene and betamethasone dipropionate HUMAN PRESCRIPTION DRUG LABEL 2 0713-0848 SUSPENSION 50 ug TOPICAL ANDA 25 sections
calcipotriene HUMAN PRESCRIPTION DRUG LABEL 1 16714-763 CREAM 50 ug TOPICAL ANDA 20 sections
Calcipotriene HUMAN PRESCRIPTION DRUG LABEL 1 40032-043 SOLUTION 0.05 mg TOPICAL ANDA 18 sections
Calcipotriene and Betamethasone Dipropionate HUMAN PRESCRIPTION DRUG LABEL 2 45802-816 OINTMENT 50 ug TOPICAL ANDA 25 sections
Calcipotriene and Betamethasone Dipropionate HUMAN PRESCRIPTION DRUG LABEL 2 51672-1402 SUSPENSION 50 ug TOPICAL ANDA 29 sections
Calcipotriene HUMAN PRESCRIPTION DRUG LABEL 1 51672-4154 OINTMENT 0.05 mg TOPICAL ANDA 21 sections
Calcitrene HUMAN PRESCRIPTION DRUG LABEL 1 51672-5278 OINTMENT 0.05 mg TOPICAL ANDA 21 sections
SORILUX HUMAN PRESCRIPTION DRUG LABEL 1 51862-376 AEROSOL, FOAM 50 ug TOPICAL NDA 29 sections
calcipotriene HUMAN PRESCRIPTION DRUG LABEL 1 51862-512 AEROSOL, FOAM 50 ug TOPICAL NDA 29 sections
Dovonex HUMAN PRESCRIPTION DRUG LABEL 1 54868-4725 CREAM 50 ug TOPICAL NDA 20 sections
Dovonex HUMAN PRESCRIPTION DRUG LABEL 1 54868-6057 SOLUTION 0.05 mg TOPICAL NDA 13 sections
Taclonex Scalp HUMAN PRESCRIPTION DRUG LABEL 2 54868-6091 SUSPENSION 50 ug TOPICAL NDA 26 sections
Calcipotriene and Betamethasone Dipropionate HUMAN PRESCRIPTION DRUG LABEL 2 63629-2520 OINTMENT 50 ug TOPICAL ANDA 24 sections
Calcipotriene and Betamethasone Dipropionate HUMAN PRESCRIPTION DRUG LABEL 2 63629-8617 OINTMENT 50 ug TOPICAL ANDA 24 sections
Calcipotriene HUMAN PRESCRIPTION DRUG LABEL 1 66993-877 CREAM 50 ug TOPICAL NDA AUTHORIZED GENERIC 21 sections
calcipotriene HUMAN PRESCRIPTION DRUG LABEL 1 66993-878 OINTMENT 50 ug TOPICAL NDA AUTHORIZED GENERIC 21 sections
Calcipotriene HUMAN PRESCRIPTION DRUG LABEL 1 68462-310 OINTMENT 50 ug TOPICAL ANDA 22 sections
calcipotriene HUMAN PRESCRIPTION DRUG LABEL 1 68462-501 CREAM 50 ug TOPICAL ANDA 20 sections
calcipotriene HUMAN PRESCRIPTION DRUG LABEL 1 68462-501 CREAM 50 ug TOPICAL ANDA 20 sections
Calcipotriene and Betamethasone Dipropionate HUMAN PRESCRIPTION DRUG LABEL 2 72162-1428 OINTMENT 50 ug TOPICAL ANDA 24 sections
CALCIPOTRIENE 0.005% / DICLOFENAC SODIUM 3% / HYALURONIC ACID SODIUM SALT 2% / NIACINAMIDE 2% HUMAN PRESCRIPTION DRUG LABEL 4 72934-2030 CREAM 0.01 g TOPICAL unapproved drug other 3 sections
CALCIPOTRIENE 0.005% / NIACINAMIDE 4% HUMAN PRESCRIPTION DRUG LABEL 2 72934-2033 CREAM 0.01 g TOPICAL unapproved drug other 4 sections
CALCIPOTRIENE 0.005% / CLOBETASOL PROPIONATE 0.05% HUMAN PRESCRIPTION DRUG LABEL 2 72934-4029 SOLUTION 0.01 g TOPICAL unapproved drug other 4 sections
CALCIPOTRIENE 0.005% / CLOBETASOL PROPIONATE 0.05% HUMAN PRESCRIPTION DRUG LABEL 2 72934-4029 SOLUTION 0.01 g TOPICAL unapproved drug other 4 sections
CALCIPOTRIENE 0.005% / TRIAMCINOLONE ACETONIDE 0.1% HUMAN PRESCRIPTION DRUG LABEL 2 72934-5034 OINTMENT 0.01 g TOPICAL unapproved drug other 4 sections
Wynzora HUMAN PRESCRIPTION DRUG LABEL 2 73499-001 CREAM 50 ug TOPICAL NDA 27 sections
Attero HUMAN PRESCRIPTION DRUG LABEL 2 87143-100 SOLUTION 0.05 mg TOPICAL ANDA 28 sections
Pellix HUMAN PRESCRIPTION DRUG LABEL 1 87143-300 SOLUTION 0.05 mg TOPICAL ANDA 22 sections